Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/cegh

Original Article

Outcome of neonates with severe hyperbilirubinemia in a tertiary level neonatal unit of North India

Mala Kumar, Shalini Tripathi*, S.N. Singh, Vikrant Anand

Department of Pediatrics, KGMU, India

ARTICLE INFO

Article history:

Received 2 February 2015

Accepted 26 May 2015

Available online 29 June 2015

Keywords:

ABE

Neonates

Risk factors

Severe hyperbilirubinemia

Outcome

ABSTRACT

Objectives: The primary objective was to determine the outcome, in terms of mortality and development of bilirubin encephalopathy, of neonates with severe hyperbilirubinemia. The secondary objective was to determine the possible risk factors for development of acute bilirubin encephalopathy (ABE).

Methods: Consecutive neonates of >35 weeks gestation admitted to Neonatal Intensive Care Unit (NICU) with a serum bilirubin >20 mg% in first 72 h of life or >25 mg% later were enrolled in the study. The clinical and demographic characteristics of the neonates were recorded. Neonates were treated with phototherapy and exchange transfusion as required.

Outcome in terms of mortality and development of bilirubin encephalopathy was noted. Discharged neonates were followed at 1, 3, and 6 months for chronic bilirubin encephalopathy (CBE).

Results: Out of 64 neonates enrolled, 28 (44%) were admitted with ABE. Four with ABE left against medical advice. Out of 60 neonates studied, 5 (8.3%) expired. A total of 17 (89.5%) neonates of ABE group and 25% of all neonates developed CBE on follow-up. A lower weight on admission (2254.68 ± 417 g vs 2481.75 ± 369 g; $p = 0.0195$), ABO/Rh incompatibility (odds ratio 4.00; 95% CI: 1.13–14, $p = 0.030$), a positive Coomb's test (odds ratio 5.7; 95% CI: 1.53–21.4, $p = 0.0096$), culture-proven sepsis (odds ratio 16; 95% CI: 0.82–312, $p = 0.067$), and normal vaginal delivery (odds ratio 5.5; 95% CI: 1.1–27.4, $p = 0.037$) were found to be significant risk factors for development of ABE.

Conclusion: Nearly half of the neonates admitted in a tertiary care NICU with severe hyperbilirubinemia had features of ABE on admission. The risk was more if they were born vaginally, had a lower weight on admission, had blood group incompatibility with positive Coomb's test, and had sepsis.

© 2015 INDIACLEN. Published by Elsevier, a division of Reed Elsevier India, Pvt. Ltd. All rights reserved.

* Corresponding author. Mobile: +91 9235237435.

E-mail address: shalini.avasthi@rediffmail.com (S. Tripathi).

<http://dx.doi.org/10.1016/j.cegh.2015.05.003>

2213-3984/© 2015 INDIACLEN. Published by Elsevier, a division of Reed Elsevier India, Pvt. Ltd. All rights reserved.

1. Introduction

Neonatal jaundice is feared due to its potential to cause Bilirubin Induced Neurological Dysfunction (BIND). After the universal use of rhesus immunoglobulin in developed countries, the incidence of kernicterus decreased remarkably, so much so that it became a rare identity and gradually pediatricians became complacent about hyperbilirubinemia. American Academy of Pediatrics had recommended 25–29 mg/dl of serum bilirubin as the cut-off for exchange transfusion in term babies with non-hemolytic jaundice based on the extremely rare occurrence of kernicterus in this group.^{1,2} However there was a resurgence of kernicterus in the 1990s due to non-hemolytic causes. This happened in temporal association with profound changes in maternal (enhanced prevalence of breastfeeding) and medical (early hospital discharge) behaviors.³ A pilot kernicterus registry in the United States shows 125 babies with kernicterus enrolled in the registry from 1984 to 2002. All but 4 (97%) of these babies had been discharged from hospital in less than 72 h after birth.⁴ Another pilot USA registry concluded that the increase in the kernicterus cases was due to inability to identify at-risk infants and to manage them in a timely manner.⁵ In Denmark, 8 cases of kernicterus were reported from 1994 to 2002, whereas no cases had been reported for the preceding 20 years.⁶ Between, 2002 and 2005, a more vigilant approach was taken for the management of newborn jaundice, and no more cases were reported.⁷ A study from India done by Murki reported an incidence of 21.8% of kernicterus in neonates with non-hemolytic hyperbilirubinemia.⁸ Kanya Mukhopadhyay from India studied newborns with ABE and followed them up for their neurodevelopmental outcome. She did not study the risk factors associated with ABE.⁹

These observations prompted us to find the overall occurrence and the risk factors for development of ABE and CBE in our part of the country where bilirubin levels greater than 30 mg/dl, presence of ABE at the time of admission, and inadequate treatment are rampant.

2. Methods

This prospective observational study was conducted over a period of 1 year in a level III NICU and outpatient department of Pediatrics of a tertiary care teaching hospital after seeking approval from the institute's ethics committee. An informed consent was obtained from the parents before enrolment of the neonates. All consecutive neonates more than 35 weeks of gestation admitted in the NICU with a serum bilirubin >20 mg % in first 72 h of life or >25 mg% after first 72 h formed the study subjects.¹⁰ Neonates with Apgar score <3 at 5 min, hypoxic ischemic encephalopathy at stage 3, major congenital malformations, conjugated bilirubin >2 mg%, metabolic disorders, and meningitis were excluded. Baseline characteristics of the neonates and their mothers were noted. The neonates were followed closely during the hospital stay. ABE was diagnosed in the presence of the following clinical features: Early phase (Stage I): hypotonia, lethargy, high pitched cry, and poor suck; Intermediate phase (Stage II): irritability,

opisthotonos, seizures, apnea, oculogyric crisis, hypertonia, and fever; and Advanced phase (Stage III): pronounced opisthotonos, shrill cry, apnea, seizures, and death.¹¹ The neonates were managed according to the American Academy of Pediatrics, 2004 guidelines.¹² Phototherapy units used were Compact Fluorescent Lamp (CFL), fiberoptic, and light emitting diode (LED) with the spectral irradiance of 10–30 $\mu\text{W}/\text{cm}^2/\text{nm}$. Double volume exchange transfusion (ET) was performed as an isovolumetric procedure by the umbilical vein or by peripheral artery and vein using fresh whole blood. For Rh isoimmunization, Rh negative and blood group 'O' or that of the baby's suspended in AB plasma, cross-matched with baby's and mother's blood was used; for ABO incompatibility, Rh compatible and blood group 'O' (not that of the baby) suspended in AB plasma, cross-matched with baby's and mother's blood was used; and for other situations, baby's group and Rh type, cross-matched with baby's and mother's blood was used for ET.

All neonates were investigated for serum bilirubin (direct, indirect, and total by photometric test using 2,4-dichloroaniline), blood group, hematocrit, reticulocyte count, Coomb's test, G6PD levels, serum albumin, and blood culture. All neonates were followed up closely during hospitalization. Enrolment was done in the initial 6-month period. Discharged neonates were followed in OPD at 1, 3, and 6 months of age. Neurological assessment of the neonates was done in accordance with the age specific norms, as per Amiel-Tison.¹³ Audiological evaluation was done at 3 months of age by Oto Acoustic Emission (OAE) and Brain stem evoked reflex audiometry (BERA) at 3 months of age. Infant showing any of the following features on follow-up were designated to have Chronic Bilirubin Encephalopathy (CBE): tone abnormality, upward gaze palsy, abnormal OAE/Brain stem evoked audiometry (BERA), and choreoathetoid movements.¹¹

2.1. Statistical methods

Data were analyzed using statistical software package, STATA 8.2. Proportions were compared using chi-square statistics and the risk was presented in terms of odds ratio (OR) with 95% confidence interval (95% CI). Fisher's exact *p*-value was reported. Two sample *t* tests were used to see the difference between the means of two different groups, if data were normally distributed. If data were not normally distributed, a non-parametric equivalent of two-sample *t*-test was used. Mann–Whitney test was used to test the level of significance between two values. Difference between two values was considered to be significant if *p* value was found to be <0.05.

3. Results

During the study period, a total of 128 neonates met the inclusion criteria. Of these, 64 neonates were not included as 28 were preterm, 10 had meningitis, 22 had HIE and 4 had major congenital malformations. A total of 64 neonates were enrolled. All patients were outborn. Causes of jaundice in the study neonates were Rh incompatibility in 15 (25%), ABO incompatibility in 25 (41.6%), cephalhematoma in 2 (3.3%), breast milk jaundice in 2 (3.3%), and unknown etiology in 16

Table 1 – Demographic details of the study patients.

Variable	ABE (n = 24)	No ABE (n = 36)	p value
Age at admission (h) (mean ± SD)	123.11 ± 75.95	133.44 ± 73.09	0.5831
Sex (M:F)	2.1:1	1.39:1	0.603
Weight at admission (g) (mean ± SD)	2254.68 ± 417.42	2481.75 ± 368.77	0.0195
Small for gestational age	3	3	1.000
Low socioeconomic status	16	17	0.461
Cause of severe hyperbilirubinemia			0.025
Rh incompatibility	7	8	
ABO incompatibility	13	12	
Cephalhematoma	2	0	
Breast milk jaundice	0	2	
Not known	2	14	
Antenatal care	26	34	1.000
Hematocrit levels (mean ± SD)	48.25 ± 3.72	49.14 ± 3.77	0.3499
Reticulocyte count	2.075 ± 1.32	2.56 ± 2.40	0.7803

(26.6%). Among 64 neonates enrolled, 28 (44%) had ABE (Stage 2, 3) on admission. Four with ABE left against medical advice within 48 h of admission. Of the 60 neonates that left, 5 (8.3%) died and 55 (91.7%) were discharged. Three died due to ABE in the ABE group and 2 due to sepsis in the group without ABE. Out of 36 neonates who did not have ABE on admission, none developed it during hospital stay. As shown in Table 1, both the study groups were comparable with respect to age (123.11 ± 75.95 h vs 133.44 ± 73.09 h; $p = 0.5831$), sex (male/female 2.1:1 vs 1.39:1; $p = 0.603$), presence of SGA babies (3[0.10%] vs 3 [0.083%]; $p = 1.00$), socioeconomic status ($p = 0.461$), and antenatal care ($p = 1.00$). However, neonates with ABE weighed less on admission than those without ABE (2254.68 ± 417 g vs 2481.75 ± 369 g; $p = 0.0195$) and the causes of hyperbilirubinemia ($p = 0.025$) were significantly different.

Of 28 neonates with ABE, 20 presented in stage II and 8 presented in stages III of ABE. Table 2 shows the risk factors associated with development of ABE. A lower weight on admission (2254.68 ± 417 g vs 2481.75 ± 369 g; $p = 0.0195$), ABO/Rh incompatibility (odds ratio 4.00; 95% CI: 1.13–14, $p = 0.030$), a positive Coomb's test (odds ratio 5.7; 95% CI: 1.53–21.4, $p = 0.0096$), culture-proven sepsis (odds ratio 16; 95% CI: 0.82–312, $p = 0.067$), and normal vaginal delivery (odds ratio 5.5; 95% CI: 1.1–27.4, $p = 0.037$) were found as statistically significant risk factors for development of ABE. However top feeding (odds ratio = 0.71; 95% CI: 1–2.6, $p = 6.36$), early discharge from the hospital (odds ratio 1.32; 95% CI: 0.28–6.1,

$p = 0.721$), history of jaundice in another sibling (odds ratio = 1.3; 95% CI: 0.42–4, $p = 0.65$), G-6-PD deficiency, and hypoalbuminemia (serum albumin <2.5 g/dl) were not significant as risk factors for ABE. The odd of association of delivery conducted at home with ABE was 5, but it was statistically not significant (odds ratio 5; 95% CI: 0.48–51.2, $p = 0.17$).

As shown in Fig. 1, 21 neonates of the group with ABE and 34 of the group without ABE were discharged. In ABE group, 19 (90.4%) turned up for follow-up and 17 (89%) had evidence of CBE. In no ABE group, only 26 (76%) neonates came for follow-up. All of them had normal neurological examination on follow-up except one who had increased tone at 1-month follow-up but did not return for further follow-ups. Of 60 neonates studied, OAE as a screening was done in all and was found to be normal in all. BERA could be done in only 8 neonates, and it was normal in all of them. MRI could not be done in any of them due to financial constraints.

4. Discussion

The primary objective of our study was to determine the outcome of neonates with severe hyperbilirubinemia. The high prevalence could be because of lack of predischARGE assignment of hyperbilirubinemia in most health facilities in our area, lack of awareness about the proper management of neonatal jaundice, and paucity of well-functioning intensive

Table 2 – Risk factors for development of acute bilirubin encephalopathy.

Risk factor	ABE (n = 24) (%)	No ABE (n = 36) (%)	p value
Weight (g) on admission (mean ± SD)	2254.679 ± 417	2481.75 ± 369	0.0195
Delivery conducted at home	3 (12.5)	1 (2.7)	Odds ratio = 5; 95% CI: 0.48–51.2, $p = 0.17$
Top feeding	19 (79.1)	32 (88.8)	Odds ratio = 0.71; 95% CI: 0.19–2.6, $p = 6.36$
Presence of Rh or ABO incompatibility	20 (83.3)	20 (55.5)	Odds ratio = 4.00; 95% CI: 1.13–14, $p = 0.03$
Positive Coomb's test	10 (41.6)	4 (11.1)	Odds ratio = 5.7; 95% CI: 1.53–21.4, $p = 0.0096$
History of jaundice in other siblings	8 (33.3)	10 (27.7)	Odds ratio = 1.3; 95% CI: 0.42–4, $p = 0.65$
G6PD deficiency	0	0	
Culture-proven sepsis	4 (14.2)	0	Odds ratio = 16; 95% CI: 0.82–312, $p = 0.067$
Hypoalbuminemia	0	0	
Normal vaginal delivery	22 (91.6)	24 (66.6)	Odds ratio = 5.5; 95% CI: 1.1–27.4, $p = 0.037$
Early discharge (within 48 h)	23 (95.8)	29 (80.5)	Odds ratio = 1.32; 95% CI: 0.28–6.1, $p = 0.721$

Significant p values are in bold.

Fig. 1 – Follow-up chart of the study cases.

phototherapy units. Overall mortality was 8.3% and ABE related mortality was 5%. Of the 64 neonates enrolled in the present study, 28 (44%) had ABE on admission. The occurrence of a poor outcome was much less in other studies from the west. Johnson et al. from pilot USA kernicterus registry reported clinical signs of ABE in 7 of 125 (5.6%) infants.⁵ Manning et al. observed that 14 out of 108 (12.9%) infants with hyperbilirubinemia had evidence of bilirubin encephalopathy and out of these 3 (2.7%) died.¹⁴ Newman et al. reported that out of 140 newborns with bilirubin level >25 mg/dl, none had kernicterus, but 14 had questionable or abnormal neurological examination.¹⁵ This may be because neonates of Asian origin are more susceptible for developing ABE.⁸ A study from India by Murki et al. reported ABE in 21.8% of 64 neonates with serum bilirubin >18 mg%.⁸ The lower incidence of ABE in this study as compared to ours was because they only included neonates without hemolysis.

One of the risk factors found by us to be associated with ABE was lower weight on admission. In our study the actual birth weight and the gestation of most of the neonates were not known as all the cases were outborn. It is possible that a lower weight on admission in ABE patients was due to their being <35 weeks gestation or due to the presence of some dehydration. Both the factors are implicated in causing BIND.

In our study, 92% of neonates with ABE were delivered vaginally in comparison to 67% in those without ABE. This observation is similar to that reported by Murki et al. where 90% of kernicteric babies had been delivered vaginally as

against 74% neonates without kernicterus.⁸ The reason could be that babies born vaginally are discharged early from the hospital.

We found that more neonates who were discharged early developed ABE than those discharged after 48 h. However, this was statistically not significant. Early discharge of neonates from the hospital causes delayed diagnosis of jaundice and an increased risk of kernicterus as reported by Harris et al. who in their study of 6 term neonates with serum bilirubin levels >25 mg% reported ABE in 80% of cases discharged within 48 h of birth.¹⁶ Similarly, a Canadian study concluded that high readmission rate within days after initial discharge indicates a need for a more thorough assessment of newborn infants and consideration of strategies to identify at-risk newborns, such as predischarge measurement of serum bilirubin.¹⁷

Infections predispose a neonate for ABE by increasing the permeability of the blood brain barrier to bilirubin. Also the binding of bilirubin to albumin, uptake of bilirubin into hepatocytes for conjugation, and the process of conjugation are all known to be stunted in the presence of sepsis.¹⁰ We found that culture-proven septicaemia was significantly associated with development of ABE. The same association is reported by Hanco et al.¹⁸ However, in a study which included only 6 neonates, this association was not found.¹⁶

Of the 24 neonates with ABE, 10 (41.6%) were Coomb's test positive. However in the group without ABE, only 4 (11.1%) were Coomb's test positive. The difference was statistically significant ($p = 0.0096$). E. Hanco and R. Lindemann in their

study of 3 neonates with kernicterus reported ABE developing in none of the neonates having positive Coomb's test.¹⁸ This was also observed by F. Ebbesen and a Canadian study.^{6,17}

Unlike the findings of Murki et al. who reported that the proportion of neonates receiving exclusive breast feeding was lesser (57%) in babies with kernicterus compared to those without kernicterus (80%),⁸ we found that feeding practices of the neonates were not risk factors for development of ABE.

Various hypotheses have been proposed for the increased propensity of Asian and Africans to bilirubin toxicity. Increased prevalence of G6PD deficiency is one major factor as reported by Stevenson et al.¹⁹ A surveillance study in UK and Ireland demonstrated that ethnic group (black) and glucose 6-phosphate dehydrogenase deficiency independently increased the risk of encephalopathy in infants with hyperbilirubinemia.¹⁴ In our study, G6PD deficiency was not found in any of the neonates studied.

In our study, the mean age at admission of neonates with ABE and without ABE was similar between 5 and 6 days. There was a male preponderance in both the groups and the difference was not statistically significant. Similarly, in the study by Murki et al., the mean age on admission of neonates with ABE was 5.5 days with a male predominance, 2.5:1 in kernicteric, and 1.17:1 in non-kernicteric babies.⁸ Also, in their study, the number of SGA babies was more in the kernicteric group (21.4%) than non-kernicteric group (6%). In our study, however, both the groups had 3 SGA neonates.

The levels of free bilirubin are higher in jaundiced neonates with lower serum albumin and hence the chance of developing ABE is greater. However, we found serum albumin levels to be similar in both kernicteric and non-kernicteric babies. This was also found by Murki et al.⁸

In the 6-month follow-up, we found that 89% of neonates admitted with ABE developed CBE despite being treated with standard guidelines. Only 1 neonate who did not have ABE on admission had increased tone at 6 months of age. So the newborns admitted without ABE and managed by standard guidelines had normal outcome in all of the cases except one. Similar study by Kanya Mukhopadhyay showed that at 1 year, 80% had abnormal neurodevelopment.⁹

In our study, we found that the actual level of serum bilirubin does not affect development of ABE rather it is the presence or absence of the risk factors which makes the difference. The study done by Gamaledin et al. also concluded that the great variation in response to total serum bilirubin (TSB) indicates that the biological factors other than TSB value are important in the pathogenesis of ABE.²⁰

There are several limitations of the present study. One was that we did not estimate free bilirubin levels, pH, and hydration status of our subjects and we could not do MRI for any of our subjects due to financial reasons. Also, we could not do BERA in all the cases. Because of finite study duration, we could follow our infants only for a period of 6 months. Some infants could have shown improvement or deterioration in neurological examination if followed up further.

The strength of the study is that the dropout rate was small and 81.8% of neonates were followed up for 6 months.

It is evident from the study that the neonates with intermediate and advanced phase of ABE had poor outcome despite adequate management. It was reassuring that 97% of

the neonates with severe hyperbilirubinemia but no ABE on admission responded well when managed according to the AAP 2004 guidelines. Most of our study population was outborn. The lack of concern of healthcare personnel regarding occurrence of severe hyperbilirubinemia is reflected in our study. There is a lack of protocol to measure predischarge bilirubin in neonates being discharged early and a paucity of effective intensive phototherapy units in birthing hospitals in our region. These could be the reasons for a dismal outcome of neonates with severe hyperbilirubinemia in our study.

Funding

None.

Conflicts of interest

All authors have none to declare.

REFERENCES

1. Practice parameters: management of hyperbilirubinemia in the healthy term newborn. *Pediatrics*. 1994;94(October (4)):558–565.
2. Johnson LH, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of kernicterus. *J Pediatr*. 2002;140(April (4)):396–403.
3. Watchko JF. Vigintiphobia revisited. *Pediatrics*. 2005;115(June (6)):1747–1753.
4. Johnson L, Brown AK. A pilot registry for acute and chronic kernicterus in term and near-term infants. *Pediatrics*. 1999;104(September (3)):736.
5. Jhonson L, Bhutani VK, Karp K, Sevieri EM, Shapiro SM. Clinical report from the pilot USA registry (1992–2004). *J Perinatol*. 2009;29(February (suppl 1)):S25–S45.
6. Ebbesen F. Recurrence of kernicterus in term and near-term infants in Denmark. *Acta Paediatr*. 2000;89(October (10)):1213–1217.
7. Ebbesen F, Andersson C, Verder H, Grytter C, Pedersen-Bjergaard L, Petersen JR. Extreme hyperbilirubinaemia in term and near-term infants in Denmark. *Acta Paediatr*. 2005;94(January (1)):59–64.
8. Murki S, Kumar P, Majumdar S, Marwah N, Narang A. Risk factors for kernicterus in neonates with non haemolytic jaundice. *Indian Pediatr*. 2001;38(July (7)):757–762.
9. Mukhopadhyay K, Chowdhary G, Singh P, Kumar P, Narang A. Neurodevelopmental outcome of acute bilirubin encephalopathy. *J Trop Pediatr*. 2010;56(October (5)):333–336.
10. Bhutani VK, Johnson LH. Kernicterus: lessons for the future from a current tragedy. *Neoreviews*. 2003;4:30–32.
11. Martin CR, Cloherty JP. Neonatal hyperbilirubinemia. In: Cloherty JP, Eichenwald EC, Stark AR, eds. *Manual of Neonatal Care* 6th ed. 2008; 181–212.
12. Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics*. 2004;114(July (1)):297–316.
13. Amiel-Tison C. Update of the Amiel-Tison neurologic assessment for the term neonate or at 40 weeks corrected age. *Pediatr Neurol*. 2002;27:196–221.

14. Manning D, Todd P, Maxwell M, Platt MJ. Prospective surveillance study of severe hyperbilirubinaemia in the newborn in the UK and Ireland. *Arch Dis Child Fetal Neonatal Ed.* 2007;92(September (5)):342–346.
15. Newman TB, Liljestrand P, Jeremy RJ, Ferriero DM, Wu YW, Hudes ES. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. *N Engl J Med.* 2006;354(May (18)):1889–1900.
16. Harris MC, Bernbaum JC, Polin JR, Zimmerman R, Polin RA. Developmental follow-up of breastfed term and near-term infants with marked hyperbilirubinemia. *Pediatrics.* 2001;107:1075–1080.
17. Sgro M, Campbell D, Shah V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. *CMAJ.* 2006;175(September (6)):587–590.
18. Hanko E, Lindemann R, Hansen TW. Spectrum of outcome in infants with extreme neonatal jaundice. *Acta Paediatr.* 2001;90:782–785.
19. Stevenson DK, Fanaroff AA, Maisels MJ, Young BW, Wong RJ, Vreman HJ. Prediction of hyperbilirubinemia in near term and term neonates. *Pediatrics.* 2001;108:31–39.
20. Gamaledin R, Iskander I, Seoud I, et al. Riskfactors for neurotoxicity in newborns with hyperbilirubinemia. *Pediatrics.* 2011;128(4).